Investor Relations
Investor Relations
Myrexis, Inc. is a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.
Recent Releases
Feb 3, 2012
Nov 18, 2011 Events & Presentations
Feb 9, 2012 at 4:30 PM ET |
|
||||||||||||||||||||||



